09.02.2011

Pfizer Animal Health has reported a 29% increase in revenues for 2010, the first full financial year since the company integrated the Fort Dodge business as part of its parent company’s acquisition of Wyeth pharmaceutical company.  

The Animal Health business unit has reported total sales of $3.58 billion, a 29% increase on the $2.76bn in fiscal 2009. The Wyeth deal completed early in Q4 of that year, and so the 2010 figures reflect the addition of legacy Wyeth/Fort Dodge products, says the company.  

The acquisition of Alpharma, part of the company’s purchase of King Pharmaceuticals in October 2010 has only just completed, and so has no bearing on fiscal 2010.

New Pfizer president and CEO Ian Read, has announced a reduction in the company’s planned R&D spend from the scheduled $8-$8.5 billion to $6.5-$7 billion by the end of 2012 (AnimalPharm).